Consensus InMode Ltd.

Stocks

INMD

IL0011595993

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 23:00:00 02/10/2026 +03			5-day change	1st Jan Change
14.09 ^USD	+0.28%		-1.19%	-4.08%

09-15	M.N. Business Strategy, Ltd. cancelled the acquisition of remaining shares InMode Ltd..	CI
09-09	InMode Ltd. Announces Launch Of Morpheus8 Cool On Morpheus8MAX Platform	CI

Evolution of the Average Target: InMode Ltd.

Evolution of the Target Price: InMode Ltd.

Changes in Analyst Recommendations: InMode Ltd.

b0e807b4dc37ba.TYSCCOVUIm8Td82tM3gVjfuMBni1TY_AWOyFrbx6W9w.HPfAY5ISEQ55NPvpXDRy-qvmcA2BeMSWKpSy8skYbrA98-w71wdHWVIc_Q~3db1de72bd67a13e99c8bba7a34daf6e

Analysts' recommendations: InMode Ltd.

06-25	Alert tagged to multiple companies from a research report withdrawn	RE
30/07/25	InMode Q2 revenue misses estimates	RE
29/04/25	UBS Adjusts InMode Price Target to $16.25 From $19, Maintains Neutral Rating	MT
29/04/25	BTIG Research Downgrades InMode to Neutral From Buy	MT
28/04/25	Baird Downgrades InMode to Neutral From Outperform, $16 Price Target; Shares Fall	MT
14/04/25	InMode Unlikely to Meet Street Consensus for Q1 Non-GAAP EPS, Needham Says	MT
09/01/25	Barclays Adjusts Price Target on InMode to $26 From $27, Maintains Overweight Rating	MT
01/11/24	UBS Adjusts Price Target on InMode to $19 From $17, Maintains Neutral Rating	MT
17/10/24	BTIG Initiates InMode at Buy With $25 Price Target	MT
10/10/24	UBS Adjusts Price Target on InMode to $17 From $20, Maintains Neutral Rating	MT
23/07/24	Jefferies Downgrades InMode to Hold From Buy, Adjusts Price Target to $19 From $21	MT
15/07/24	Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating	MT
12/07/24	Canaccord Genuity Adjusts InMode's PT to $16 From $21, Keeps Hold Rating	MT
03/05/24	UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating	MT
12/04/24	Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating	MT
15/02/24	Barclays Adjusts Price Target on InMode to $34 From $32, Maintains Overweight Rating	MT
14/02/24	UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating	MT
18/01/24	Barclays Trims Price Target on InMode to $32 From $33, Maintains Overweight Rating	MT
03/11/23	UBS Downgrades InMode to Neutral From Buy, Cuts Price Target to $24 From $52	MT
01/08/23	Barclays Adjusts Price Target on InMode to $54 From $47, Maintains Overweight Rating	MT
28/07/23	UBS Adjusts InMode Price Target to $52 From $48, Maintains Buy Rating	MT
28/07/23	Baird Adjusts Price Target on InMode to $61 From $53, Maintains Outperform Rating	MT
04/05/23	Barclays Adjusts Price Target on InMode to $47 From $45, Maintains Overweight Rating	MT
29/03/23	UBS Initiates Coverage on InMode With Buy Rating, $40 Price Target	MT
17/02/23	Needham Downgrades InMode to Hold From Buy as Q1 Aesthetics Patient Survey Shows Consumers Cutting Spending on Procedures	MT

More recommendations

Other Advanced Medical Equipment & Technology

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
INMODE LTD.	-	+14.74%
THERMO FISHER SCIENTIFIC, INC.		-0.3%
DANAHER CORPORATION		+9.65%
INTUITIVE SURGICAL, INC.		+21.53%
BOSTON SCIENTIFIC CORPORATION		+42.71%
EDWARDS LIFESCIENCES CORPORATION		+18.57%
SIEMENS HEALTHINEERS AG		+20.24%
AGILENT TECHNOLOGIES, INC.		+4.42%
VEEVA SYSTEMS INC.		+8.77%
WATERS CORPORATION		+5.57%
Average		+14.59%
Weighted average by Cap.		+11.79%